TRANSCRIPT

Q2 2026 — Earnings call remarks

Q2 2026PDF · 11 pages162 KB
Second Quarter 2026 Results
Teleconference Prepared Remarks
July 16, 2026
Moderator:
Good morning, and welcome to the UnitedHealth Group Second Quarter 2026
Earnings Conference Call. A question and answer session will follow
UnitedHealth Group’s prepared remarks. As a reminder, this call is being
recorded.
Here is some important introductory information. This call contains “forward-
looking” statements under U.S. federal securities laws. These statements are
subject to risks and uncertainties that could cause actual results to differ
materially from historical experience or present expectations. A description of
some of the risks and uncertainties can be found in the reports that we file with
the Securities and Exchange Commission, including the cautionary statements
included in our current and periodic filings.
This call will also reference non-GAAP amounts. A reconciliation of the non-
GAAP to GAAP amounts is available on the “Financial & Earnings Reports”
section of the Company’s Investor Relations page at
www.unitedhealthgroup.com.
Information presented on this call is contained in the Earnings Release we issued
this morning and in our Form 8-K dated July 16, 2026, which may be accessed
from the Investor Relations page of the Company’s website. I will now turn the
conference over to the chairman and chief executive officer of UnitedHealth
Group, Stephen Hemsley.
Stephen Hemsley
Thank you. Good morning, everyone, and thank you for joining us.
Our second quarter results and updated full year 2026 outlook demonstrate
continuing progress toward delivering more consistent and dependable
performance. They are a sign of stronger, broad-based performance disciplines
taking hold in each of our businesses, and a restless desire to drive mission-
aligned change across the enterprise and advance our social impact.

-- 1 of 11 --

UnitedHealthcare has improved performance in its Medicare businesses through
thoughtful benefit planning and design, all while remaining respectful of
persistently elevated medical costs.
Our Medicaid business is in line with expectations, as we continue to work with
states on ensuring appropriate rates.
Our commercial benefits business, consistent with the broader and more diverse
commercial market it serves, continues to experience higher-than-expected cost
trends due to factors Tim Noel will discuss shortly.
At Optum, we’re seeing building momentum from Optum Health as the business
re-centers back to its integrated, value-based care delivery model. This resulted
in another quarter of improved care management and greater operating
discipline.
Optum Rx continues to perform to plan as transparency initiatives we announced
early this year resonate well in the marketplace.
Optum Insight, also on plan, remains on a multi-year path of reinvestment and
innovation, as we bring modern intelligent technologies and services to the areas
of greatest need in the health system. We believe Optum Insight is exceptionally
well-positioned to help modernize and simplify the health system as it brings AI-
enabled tools and services to market.
Across the enterprise, we’re focused on serving consumers and care providers in
ways that are reliable, affordable and transparent. That requires us to pay close
attention to areas where the system isn’t working well enough – areas including
care approvals, accuracy of information and speed of response, access and
scheduling, digital services, care path navigation and more.
We are committed to making the health system work better for all stakeholders –
by simplifying processes – by being clearer, more consistent and faster in the
experience we offer and by redesigning and modernizing that experience
altogether.
AI technology is helping us move faster. We’re using it to improve service
interactions, reduce administrative burden and support better decision-making –

-- 2 of 11 --

always in service of improved experiences and outcomes for both patients and
care providers.
UnitedHealth Group has a long history of evolving to meet the needs of a
constantly changing U.S. health system. That evolution today includes a tech-
forward view actively and appropriately embracing an AI paradigm for our
businesses, a management team with skills and vision to help in building a more
advanced health system and an ever-evolving organizational structure and
culture aligned to that system. Our operating structure today broadly reflects a
set of highly regulated benefit businesses and a complementary set of products
and services for patients, care providers and customers. We will continue to look
to build and evolve ahead of the health system itself.
We’re making solid, early progress, both in how we better approach those we
serve and in our results. We have much more work ahead and need to continue
to get better by focusing on what matters most with solid management and
execution disciplines aligned to our mission to better serve people and the health
system itself.
With that, I’ll turn it over to Tim Noel.
Tim Noel
Thanks, Steve.
The pricing, benefit design and market actions we've taken over the past year
have been central in supporting our second quarter results and improved full-
year outlook. As you have seen, UnitedHealthcare’s overall performance in the
second quarter exceeded expectations, driven by better results in Medicare
Advantage while commercial benefits remain pressured.
I’ll start with medical costs, through the first half of the year, we are seeing
divergence within our portfolio. Medical cost trends in Medicare are still running
well above historical levels but below our expectations so far in 2026.
A primary reason for trend being below our expectations in Medicare is our own
initiatives, including benefit design, care management models and network
curation. Other factors have an influence as well, including prior-year

-- 3 of 11 --

development, a more favorable respiratory season and weather patterns. We
expect the 2026 Medicare medical cost trend to come in below our initial
estimate of around 10%.
Commercial costs are stubbornly high, rising above expectations, which we
believe is consistent with what is being experienced across the sector.
Turning to the overall performance of our individual benefit offerings, Medicare
delivered a stronger second quarter. Membership retention was better than
previously anticipated. We now expect full-year Medicare Advantage enrollment
to decline by approximately 1.1 million and Medicare margins to finish 2026
above 3%.
Looking to 2027 bids, our benefit planning remains disciplined and grounded in
the current trend environment. We will continue to support program and margin
stability through actions including benefit adjustments and selective changes in
market participation.
In Medicaid, overall performance during the quarter, including cost trend, was
broadly in line with expectations. We are beginning to see early signs of
improvement from initiatives including those targeting elevated behavioral health
cost trends, but we expect Medicaid margins to remain pressured for 2026. Our
focus is on closing the gap between lagging reimbursement rates and underlying
medical cost trends while continuing to partner closely with states to support the
long-term sustainability of Medicaid benefits and support them in identifying and
reducing fraud, waste and abuse.
Within our commercial offerings, as I noted, we are not yet seeing evidence of
cost trend moderation – in fact, it is the opposite, with medical cost trends
modestly above the 11% level we previously saw. The primary drivers are
pressure from the independent resolution process under the No Surprises Act,
which applies only to commercial plans; and more aggressive billing practices
among providers, especially higher service and coding intensity and higher costs
per encounter that result from the more fee for service orientation of commercial
plans. At this distance, commercial margin recovery will remain a focus area
longer than originally anticipated.

-- 4 of 11 --

Returning to UnitedHealthcare as a whole, we are confident in being able to
deliver meaningful earnings growth in 2026 and into 2027 with the reinvestments
we are making in the business to build a stronger, more durable foundation for
2027 and beyond.
Of equal, if not more, importance: We remain intent on modernizing essential
health care experiences to improve how consumers and care providers
experience the health system. For example, in the quarter we committed to
eliminating by the end of this year 30% of prior authorization volume and nearly
two-thirds of prior authorization requirements for pediatric care. We continue to
take concrete steps to reduce complexity and increase speed by further
simplifying prior authorization; increasing consumer-responsive digital
experiences; providing greater support to rural hospitals and care providers;
offering more consumer-centered product innovation; and much more.
AI is both an enabler and an accelerant to this effort. We’re early in this work but
clearly on the path to improve the healthcare experience and strengthen
relationships with our stakeholders – starting with consumers and care providers.
And we're confident these efforts will bolster UnitedHealthcare's long-term
performance and market position.
And now let me hand it to Patrick Conway.
Patrick Conway
Thanks, Tim. As Steve noted, we are seeing positive momentum across Optum,
with all three business segments performing inline or ahead of plan through the
first half of the year.
Optum Health is intently focused on improving its clinical care and operational
experience to better serve the 20 million people we care for through primary and
specialist care, ambulatory surgery and home health. Over the last year, we have
made significant changes in how we operate this business locally and nationally
and are seeing the initial benefits of this approach. We are steadfast in our intent
to optimize an integrated value-based care system that benefits patients, care
providers and taxpayers.

-- 5 of 11 --

On the clinical side, we are advancing approaches that better support care
providers and drive measurable improvements to patient care at lower costs. I’ll
offer a few examples:
• First, enhanced support for patients during key transitions of care has
resulted in an approximately 10% reduction in hospitalizations since
implementation late last year in the western and southern regions of
Optum Health.
• Second, home health initiatives to better support patients as they return
home, where they can be managed more comfortably and effectively,
have reduced readmissions. In pilots, the effort has driven a more than
20% improvement in timely care delivery, alongside reductions in acute
care utilization and shorter skilled nursing facility stays.
• And third, in rural health, we've expanded access to care by integrating
HouseCalls and home-based care capabilities, coupled with treat-in-place
offerings for patients with complex chronic and behavioral health
conditions. Today, Optum Health reaches nearly 90% of U.S. counties and
conducts approximately 2.5 million rural patient home visits annually.
We will expand these programs across our Optum Health footprint by the end of
2026.
On the operational side of Optum Health, we have established a clearer regional
and national management focus. This gives us greater and more timely visibility
into performance, driving consistent best-in-class standards across the portfolio
and deploying technologies to support clinicians in the important work they do.
There is real progress on the rollout of AI-based ambient listening capabilities,
available to 70% of our employed providers today and on track to exceed 90% by
year-end.
Collectively, these actions are yielding tangible results. Patient experience in our
care delivery sites is up approximately 5% year-over-year, and patient access
has expanded by nearly 200,000 more patient-facing hours. We are in the early
stages of these efforts.

-- 6 of 11 --

Optum Health will build upon this foundation with additional investments in
clinical workflow improvements and network performance, more deeply
embedding AI and automation to further improve operational performance and
clinician experience. Additionally, we entered the 2027 benefit planning season
very differently than years past, starting with much earlier proactive collaboration
with all our payer partners. This will translate to greater care coordination for
patients while more appropriately aligning rates and risks.
As our plans and initiatives begin to mature and scale with disciplined execution,
we expect margins to continue to steadily improve.
Turning to Optum Rx, for a few years now we have been leading an industry-
wide shift toward transparency and fee-based services, where we are delivering
affordability and better outcomes, regardless of pricing structure. That’s why we
continue to win new customers and retain existing ones, with retention rates in
the high 90s.
In May, we announced a new pharmacy care approach based on monthly per
member fees, with full PBM and GPO fee transparency and enhanced consumer
tools. Client feedback has been positive and focused on how greater
transparency and clinical alignment can address trend challenges, shifting the
conversation to affordable health outcomes versus economic guarantees.
This all builds on our industry-leading commitment last year to pass through
100% of manufacturer rebates to customers by the end of 2027. We are well on
our way, as we expect to end 2026 with more than 95% of clients on a 100%
pass-through.
Moving to Optum Insight, AI-enabled approaches continue to gain traction as
more payer and provider customers seek differentiated capabilities to drive better
performance.
The emerging suite of products includes solutions such as AI-enabled coding,
real-time payer and provider interfaces and clinical quality and safety support.
These products are driving real impact for customers, making health care
simpler, faster, better and more affordable.

-- 7 of 11 --

For example, Value Connect is an AI driven insights platform integrated into
provider workflows and electronic health records to improve value-based care
performance. Early client results include a 17% reduction in pharmacy costs.
Bringing this all together, halfway through the year we have made steady
progress in each of our Optum businesses and will continue to find ways to better
serve patients, providers, and customers.
I’ll now turn it over to Wayne DeVeydt.
Wayne DeVeydt
Thank you Patrick and good morning, everyone.
I will briefly review second quarter results then discuss expectations for the
remainder of the year as we refresh our 2026 guidance.
Overall, the quarter and full-year outlook reflect improved performance across
our businesses with notable improvements in UnitedHealthcare and Optum
Health.
UnitedHealth Group reported adjusted earnings per share of $6.38, compared to
$4.08 in the prior year. Total revenues were $112 billion, largely consistent with
the prior year, while operating earnings of $8 billion grew 55% year-over-year.
This improvement reflects product and portfolio actions taken over the past 12
months along with more focused and consistent management disciplines.
Turning to medical costs, our reported medical care ratio of 86.7% includes $860
million of net favorable prior period medical development, the majority of which is
in-year development. This compares to 89.4% in 2Q 2025. Days claims payable
was 47 days, up approximately 2.5 days from a year ago.
The operating cost ratio was 12.7% for the quarter, compared to 12.3% a year
ago, as we continued to focus on operating discipline while making targeted
investments across technology, AI, care delivery enhancements, customer
experience and advancing healthier communities through the United Health
Foundation.

-- 8 of 11 --

Moving to cash flows and our balance sheet, operating cash flows in the quarter
were approximately $11 billion, or 1.9 times net income, reflecting timing of
substantial government payments and strong earnings. This provides capital to
strengthen the balance sheet, invest in growth and return value to shareholders.
Through mid-July, we have deployed $4 billion for repurchases of 11.4 million
shares. We now expect to complete total share repurchases of at least $5 billion
in 2026, compared to initial guidance of $2.5 billion. During the quarter, we
returned $2.1 billion to shareholders through our dividend, which our Board
increased to $9.28 per share on an annualized basis. And lastly, on July 2 we
successfully closed the previously announced combination with Alegeus.
Our debt-to-capital ratio was 41.2% at the end of the quarter, compared to 44.1%
one year ago and a 170 basis point sequential improvement from the first quarter
of this year. We remain on track to reduce our debt-to-capital ratio to
approximately 40% by the end of 2026.
As you saw earlier this morning, we have updated our full year 2026 guidance to
reflect performance through the first half of the year and a more mature
understanding of expected membership mix and utilization patterns for the
remaining six months. We continue to be respectful of medical trend, and we
believe this refreshed outlook appropriately balances risks and investments with
durable run-rate earnings.
A few areas of this outlook to highlight:
We are providing new adjusted earnings per share guidance range of $19.50 to
$20, with slightly more earnings in 3Q relative to 4Q.
We are increasing the full year operating earnings outlook for UnitedHealthcare
to at least $12 billion and for Optum Health to at least $2.2 billion. These
changes reflect operational improvement underway across the enterprise. We
now expect a full-year Medical Care Ratio of 88.1%, +/- 25 basis points. We
expect the Operating Cost Ratio to come in at the higher end of our previously
discussed range as a result of investments in our people, communities and AI.
The overall earnings cadence for the year remains consistent with prior
expectations. UnitedHealthcare earnings continue to be weighted approximately

-- 9 of 11 --

75% to the first half of the year. Similarly, we expect nearly all of Optum Health's
earnings to be recognized in the first half, with modest profit in 3Q offset by
modest losses in the fourth quarter, due to the seasonality of the risk-based
businesses.
In contrast, Optum Insight and Optum Rx remain more heavily weighted toward
the second half of the year, with each expected to generate approximately 55%
of their full-year earnings during the back half as client implementations, growth
investments and normal business seasonality progress through the year. So
overall we’re seeing a two-thirds/one-third first-half to back-half mix.
Steve, back to you.
Stephen Hemsley
Thanks, Wayne.
Over the last few quarters, this enterprise has undertaken a broad-based effort to
improve how consumers and care providers experience the health system while
addressing chronic cost trend issues driving the everyday challenges of access,
affordability and complexity. Our press release this morning has a sampling of
these initiatives.
Our efforts focus on essential themes: affordability, transparency, modernization,
simplicity and convenience.
As the U.S. health system continues to evolve, we will evolve our approaches
and our businesses as a scaled and diverse enterprise – driving integrated value
based care anchored in the first principles of the right care, at the right time and
in the right setting – a system where incentives are aligned to those first
principles and the better health and the better cost trends they drive.
Value-based care approaches are a key component of the effort to make health
care more affordable by bending the cost trend by better aligning incentives for
both consumers and care providers.
Artificial intelligence technologies, applied in practical ways that help people, can
be an accelerator to achieving that goal as we use them to literally reimagine our
enterprise. You should expect us to continue along that path and pick up

-- 10 of 11 --

momentum as we better fulfill our mission, with accountability to you and all
stakeholders in the health system.
We will now go to questions. Thank you, operator.
Steve (Post-Q&A Close)
Thank you all for joining us today. We appreciate your time and your trust in us
as we continue to both improve our performance and modernize our company,
and I can assure you we still stay restless and urgent as we go forward.

-- 11 of 11 --